Galactosylated dopamine enters into the brain, blocks the mesocorticolimbic system and modulates activity and scanning time in Naples high excitability rats

Neuroscience

Volumn 152, Issue 1, 2008, Pages 234-244

  Ruocco, L A ^a   Viggiano, D ^a   Viggiano, A ^a   Abignente, E ^a   Rimoli, M G ^a   Melisi, D ^a   Curcio, A ^a   Nieddu, M ^b   Boatto, G ^b   Carboni, E ^c   Gironi Carnevale, U A ^a   Sadile, A G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

ADHD; behavior; HPLC; lectin histochemistry; Naples rat lines; prodrug

Indexed keywords

DOPAMINE; DOPAMINE SUCCINATE; GALACTOSYLDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MESENCEPHALON; NEOSTRIATUM; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DOPAMINE; GALACTOSE; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; PRODRUGS; RATS;

EID: 39649124467     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.11.021     Document Type: Article

References (57)

1. Aspide R., Fresiello A., De Filippis G., Gironi Carnevale U.A., and Sadile A.G. Nonselective attention in a rat model of hyperactivity and attention deficit: subchronic methylphenidate and nitric oxide synthesis inhibitor treatment. Neurosci Biobehav Rev 24 (2000) 59-71
2. Aspide R., Gironi Carnevale U.A., Sergeant J.A., and Sadile A.G. Non-selective attention and nitric oxide in putative animal models of attention-deficit hyperactivity disorder. Behav Brain Res 95 (1998) 123-133
3. Bentivoglio M., and Morelli M. The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. In: Dunnett S.B., Bentivoglio M., Bjorklund A., and Hokfelt T. (Eds). Handbook of chemical neuroanatomy (2005), Elsevier, Amsterdam 1-107
4. Bonina F., Puglia C., Rimoli M.G., Melisi D., Boatto G., Nieddu M., Calignano A., La Rana G., and De Caprariis P. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target 11 (2003) 25-36
5. Bonina F.P., Arenare L., Palagiano F., Saija A., Nava F., Trombetta D., and De Caprariis P. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J Pharm Sci 88 (1999) 561-567
6. Cabib S., Puglisi-Allegra S., and Ventura R. The contribution of comparative studies in inbred strains of mice to the understanding of the hyperactive phenotype. Behav Brain Res 130 (2002) 103-109
7. Capowski J.J. Computer techniques in neuroanatomy (1989), Plenum Press, New York 1-483
8. Cass W.A., and Gerhardt G.A. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci Lett 176 (1994) 259-263
9. Cerbone A., Pellicano M.P., and Sadile A.G. Evidence for and against the Naples high- and low-excitability rats as genetic model to study hippocampal functions. Neurosci Biobehav Rev 17 (1993) 295-303
10. Contin M., Martinelli P., Riva R., Dondi M., Fanti S., Pettinato C., Scaglione C., Albani F., and Baruzzi A. Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT. J Neurol 250 (2003) 1475-1481
11. Dalpiaz A., Filosa R., De Caprariis P., Conte G., Bortolotti F., Biondi C., Scatturin A., Prasad P.D., and Pavan B. Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. Int J Pharm 336 (2007) 133-139
12. Djaldetti R., and Melamed E. New therapies for Parkinson's disease. J Neurol 248 (2001) 357-362
13. Edwards A.L. Statistical methods for the behavioral sciences (1967), Holt, Rinehart and Winston, New York
14. Einhorn L.C., Johansen P.A., and White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 8 (1988) 100-112
15. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
16. Fernandez C., Nieto O., Rivas E., Montenegro G., Fontenla J.A., and Fernandez-Mayoralas A. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res 327 (2000) 353-365
17. Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 29 (2004) 15-30
18. Garris P.A., Ciolkowski E.L., Pastore P., and Wightman R.M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14 (1994) 6084-6093
19. Gironi Carnevale U.A., Vitullo E., Varriale B., Ruocco L.A., and Sadile A.G. A classical Mendelian cross-breeding study of the Naples high and low excitability rat lines. Behav Brain Res 183 (2007) 130-140
20. Grace A.A., Bunnney B.S., Moore H., and Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20 (1997) 31-37
21. Halmos T., Santarromana M., Antonakis K., and Scherman D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol 318 (1996) 477-484
22. Hölm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
23. Imperato A., Tanda G., Frau R., and Di Chiara G. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J Pharmacol Exp Ther 245 (1988) 257-264
24. Ingram S.L., Prasad B.M., and Amara S.G. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci 5 (2002) 971-978
25. Lacey M.G., Mercuri N.B., and North R.A. On the potassium conductance increase activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones. J Physiol 401 (1988) 437-453
26. Leo D., Sorrentino E., Volpicelli F., Eyman M., Greco D., Viggiano D., di Porzio U., and Perrone-Capano C. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 27 (2003) 661-669
27. Lindvall O., and Bjorklund A. The organization of ascending catecholamine neuron systems in the rat brain as revealed by glyoxylic acid fluorescence method. Histochemistry 39 (1974) 97-127
28. Mercuri N.B., and Bernardi G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol Sci 26 (2005) 341-344
29. Mercuri N.B., Scarponi M., Bonci A., Siniscalchi A., and Bernardi G. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 17 (1997) 2267-2272
30. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
31. Mueckler M. Facilitative glucose transporters. Eur J Biochem 219 (1994) 713-725
32. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., and Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 (2004) 997-1005
33. Oldendorf W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 221 (1971) 1629-1639
34. Paladini C.A., Robinson S., Morikawa H., Williams J.T., and Palmiter R.D. Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci U S A 100 (2003) 2866-2871
35. Pisani A., Centonze D., Bernardi G., and Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 20 (2005) 395-402
36. Pliszka S.R. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 1385-1390
37. Polt R., Porreca F., Szabo L.Z., Bilsky E.J., Davis P., Abbruscato T.J., Davis T.P., Harvath R., Yamamura H.I., and Hruby V.J. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A 91 (1994) 7114-7118
38. Ruocco L.A., Viggiano D., Pignatelli M., Iannaccone T., Rimoli M.G., Melisi D., Curcio A., De Lucia S., Carboni E., Gironi Carnevale U.A., de Caprariis P., and Sadile A.G. Galactosylated dopamine increases attention without reducing activity in c57bl/6 mice. Behav Brain Res (2007) in press
39. Ruskin D.N., Bergstrom D.A., Shenker A., Freeman L.E., Baek D., and Walters J.R. Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol Psychiatry 49 (2001) 340-350
40. Sadile A.G., Gironi Carnevale U.A., Vitullo E., Cioffi L.A., Welzl H., and Bättig K. Maze learning of the Naples high- and low-excitability rat lines. Adv Biosci 70 (1988) 177-180
41. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 24 (2000) 31-40
42. Sagvolden T., Johansen E.B., Aase H., and Russell V.A. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28 (2005) 397-419
43. Schmitz Y., Lee C.J., Schmauss C., Gonon F., and Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 21 (2001) 5916-5924
44. Schmitz Y., Schmauss C., and Sulzer D. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J Neurosci 22 (2002) 8002-8009
45. Sergeant J.A., Geurts H., Huijbregts S., Scheres A., and Oosterlaan J. The top and the bottom of ADHD: a neuropsychological perspective. Neurosci Biobehav Rev 27 (2003) 583-592
46. Shimura T., Tabata S., Terasaki T., Deguchi Y., and Tsuji A. In-vivo blood-brain barrier transport of a novel adrenocorticotropic hormone analogue, ebiratide, demonstrated by brain microdialysis and capillary depletion methods. J Pharm Pharmacol 44 (1992) 583-588
47. Silva M.A., Mattern C., Hacker R., Tomaz C., Huston J.P., and Schwarting R.K. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse 27 (1997) 294-302
48. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94 (1998) 127-152
49. Souza Silva M.A., Mattern C., Hacker R., Nogueira P.J., Huston J.P., and Schwarting R.K. Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat. J Neurochem 68 (1997) 233-239
50. Triguero D., Buciak J., and Pardridge W.M. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54 (1990) 1882-1888
51. Uchimura N., Higashi H., and Nishi S. Hyperpolarizing and depolarizing actions of dopamine via D-1 and D-2 receptors on nucleus accumbens neurons. Brain Res 375 (1986) 368-372
52. Uriel C., Egron M.J., Santarromana M., Scherman D., Antonakis K., and Herscovici J. Hexose keto-C-glycoside conjugates: design, synthesis, cytotoxicity, and evaluation of their affinity for the glucose transporter Glut-1. Bioorg Med Chem 4 (1996) 2081-2090
53. Viggiano D., Grammatikopoulos G., and Sadile A.G. A morphometric evidence for a hyperfunctioning mesolimbic system in an animal model of ADHD. Behav Brain Res 130 (2002) 181-189
54. Viggiano D., Vallone D., Welzl H., and Sadile A.G. The Naples high-and low excitability rats: selective breeding, behavioral profile, morphometry and molecular biology of the mesocortical dopamine system. Behav Genet 32 (2002) 315-333
55. Viggiano D., Vallone D., Ruocco L.A., and Sadile A.G. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci Biobehav Rev 27 (2003) 683-689
56. Viggiano D., Vallone D., and Sadile A.G. Dysfunctions in the dopamine systems and ADHD: evidences from animals and modeling. Neural Plast 11 (2004) 93-116
57. Wu Q., Reith M.E., Walker Q.D., Kuhn C.M., Carroll F.I., and Garris P.A. Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J Neurosci 22 (2002) 6272-6281